FDA Class II Recall: The Medicine Shoppe Pharmacy Cites Processing Control Lapses for Hormone Compound
The Medicine Shoppe Pharmacy initiated a Class II recall for its Bi-Est/Progesterone/Testosterone compounded hormone product due to a critical 'Lack of Processing Control' at its Port Charlotte, FL facility. This event, terminated in December 2022, underscores the FDA's heightened focus on quality assurance in compounding pharmacies. Decision-makers must reassess supplier qualification protocols and internal oversight for compounded pharmaceutical sourcing to mitigate regulatory and supply chain risks.
FDA Class II Recall: The Medicine Shoppe Pharmacy Cites Processing Control Lapses for Hormone Compound
The U.S. Food and Drug Administration (FDA) announced a Class II recall initiated by The Medicine Shoppe Pharmacy, located at 3524b Tamiami Trl, Port Charlotte, Florida, United States, for a compounded hormone preparation. The affected product is identified as "Bi-Est (1:1)/Progesterone/Testosterone 2.5/150/1.5 mg/mL Versabase CR 90 mL bottle, Rx." This specific formulation, intended for prescription use, was distributed exclusively within Florida. The recall, designated D-1217-2020, was voluntarily initiated by the firm on April 6, 2020, and officially terminated by the FDA on December 13, 2022. The primary reason cited for this significant action was a "Lack of Processing Control." For procurement directors and supply chain VPs, this directly translates to a critical breakdown in the manufacturing process that could compromise product quality, efficacy, and patient safety. The affected lot, number 45280, carried a discard date of September 23, 2020, with only one 90 mL bottle of the compounded product identified in the recall. This event underscores the imperative for stringent quality management systems, even within smaller compounding operations, to prevent deviations that necessitate regulatory intervention and potential market disruption.
Regulatory Scrutiny Intensifies on Compounding Pharmacies' Quality Systems
The "Lack of Processing Control" identified in The Medicine Shoppe Pharmacy's recall highlights a persistent area of concern for the FDA regarding compounding pharmacies. This classification of a Class II recall indicates that the use of, or exposure to, the recalled product may cause temporary or medically reversible adverse health consequences, or that the probability of serious adverse health consequences is remote. For regulatory affairs heads, this event serves as a clear signal that the FDA maintains a vigilant stance on the quality and safety of compounded medications, particularly those involving sensitive hormone therapies like Bi-Est, Progesterone, and Testosterone. This incident, while specific to a single compounded product and limited distribution, resonates with broader industry trends. For instance, recent parallel events, such as the FDA Class II Recall of Essential Wellness Pharma's Progesterone Injection due to sterility assurance failures, reinforce the ongoing regulatory focus on hormone preparations. Business development executives must recognize that the regulatory landscape for compounded drugs is dynamic, demanding robust internal quality assurance programs and meticulous adherence to Good Manufacturing Practices (GMP) to avoid similar compliance issues. The voluntary nature of the recall suggests the firm identified the issue, but the underlying control lapse points to systemic weaknesses that require comprehensive remediation.
Strategic Risk Mitigation for Sourcing Compounded Pharmaceutical Products
For procurement directors and supply chain VPs, the recall by The Medicine Shoppe Pharmacy underscores the critical importance of rigorous due diligence when sourcing compounded pharmaceutical products. A "Lack of Processing Control" directly impacts the reliability and quality of the finished product, posing significant risks to patient outcomes and potentially leading to costly supply chain disruptions. Companies relying on compounded hormone therapies, such as Bi-Est, Progesterone, or Testosterone, must implement enhanced supplier qualification processes that extend beyond basic licensing to include in-depth audits of a compounding pharmacy's quality management systems, manufacturing controls, and personnel training. Regulatory affairs teams should proactively assess their organization's exposure to similar risks by reviewing internal policies for compounded drug procurement and usage. This includes verifying that all third-party compounding partners have demonstrably robust quality control measures in place, capable of preventing and detecting processing deviations. While this recall involved a single bottle, the principle of inadequate control can apply to larger operations. Diversifying sourcing strategies and establishing clear quality agreements with compounding pharmacies are essential steps to mitigate the commercial and regulatory risks associated with such quality lapses, ensuring continuity of supply and patient safety.